Learn how SGLT2 inhibitors affect hemoglobin and hematocrit, and what a JAMA meta-analysis reveals about possible heart and kidney benefits.
Read More »Can Better Self-Management Protect the Kidneys Before Damage Takes Hold?
Can better diabetes self-management protect kidney health? Explore new trial findings on A1C, blood pressure, cholesterol, and kidney function.
Read More »SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?
SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …
Read More »Dialysis Changes the Rules: What Happens When Patients With Diabetes Use Real-Time CGM?
Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …
Read More »Your Eye Exam May Be Predicting More Than Vision Loss: AI Is Finding Hidden Diabetes Risks
For people with diabetes, a retinal photograph has traditionally answered one major question: Is diabetic retinopathy developing? However, artificial intelligence is beginning to uncover much more. Emerging retinal AI models for systemic risk assessment can detect patterns associated with cardiovascular disease, kidney disease, blood pressure, and metabolic health. As a …
Read More »Can AI and Digital Pathology Detect Diabetic Kidney Disease Earlier?
Artificial intelligence is rapidly changing how healthcare professionals diagnose disease. But can computers identify kidney damage before it becomes obvious under a microscope? Researchers believe the answer may be yes. The combination of digital pathology, artificial intelligence, and diabetic kidney disease research is opening new opportunities to identify microscopic kidney …
Read More »Why Cardiologists Are Looking Beyond Traditional SGLT2 Therapy
The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By …
Read More »A Newly Discovered Form of Cell Death May Explain Why Diabetes Causes So Many Complications
Diabetes is known for raising blood sugar levels, but its long-term complications often have the greatest impact on health. Kidney disease, vision loss, nerve damage, and cardiovascular disease affect millions of people living with diabetes. For years, researchers focused on inflammation, oxidative stress, and poor circulation to explain these complications. …
Read More »Not All Diabetic Kidney Disease Is the Same—Scientists Just Found a Hidden Subtype
For years, diabetic kidney disease (DKD) has been viewed as a single condition that progresses in a fairly predictable way. However, new research suggests that this assumption may overlook important biological differences between patients. Scientists have now identified a previously hidden subtype of diabetic kidney disease marked by increased B-cell …
Read More »Farxiga Just Went Generic—Will Lower Prices Finally Change Diabetes Care?
For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.